{"analyses":[{"ciLowerLimit":"0.51","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.81","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.64"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.3","upperLimit":"18.6","value":"13.8"},{"groupId":"OG001","lowerLimit":"7.4","upperLimit":"9.3","value":"8.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"185"}],"units":"Participants"}],"description":"Duration of Response (DOR) was defined as the time from the first documented evidence of a CR (disappearance of all evidence of target lesions) or a PR (at least a 30% reduction from Baseline in the sum of the longest diameter of all target lesions) until disease progression or death due to any cause. PD was defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of at least1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation. Data were summarized per RECIST, Version 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dabrafenib 150 milligrams (mg) orally twice daily (BID) and Trametinib 2 mg orally once daily until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Dabrafenib Plus Trametinib"},{"description":"Vemurafenib 960 mg orally BID until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"Vemurafenib"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population. Only participants with confirmed response by RECIST version 1.1 were included.","reportingStatus":"POSTED","timeFrame":"From the time of the first documented response (CR or PR) until disease progression (up to approximately 6 years)","title":"Duration of Response (DOR), as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Months"}